Overview

• Elicio's Q3 2025 net loss narrows to $10.1 mln from $18.8 mln in Q3 2024

• Company raised $11.1 mln since Q3 2025, extending cash runway through Q2 2026

• Phase 2 AMPLIFY-7P trial shows fewer disease progressions than projected

Outlook

• Company anticipates Phase 2 DFS analysis in 1H 2026

• Elicio expects cash to support operations through Q2 2026

• Company plans FDA meeting post-DFS analysis for Phase 3 design

Result Drivers

• CASH RUNWAY EXTENSION - Co raised $11.1 mln since beginning of Q3, extending cash runway through Q2 2026, supporting operations beyond anticipated DFS endpoint analysis

• OPERATING EXPENSES - Fell to $8.05 mln from $10.34 mln last year, with R&D expenses down by $2.2 mln due to lower clinical trial costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Elicio Therapeutics Inc is $15.50, about 40.7% above its November 12 closing price of $9.19

Press Release: ID:nGNXb5XTh

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)